Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Aptose Biosciences (APTO) Share Price

News headlines about Aptose Biosciences (NASDAQ:APTO) (TSE:APS) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aptose Biosciences earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.0579336368058 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern’s analysis:

Several analysts recently weighed in on APTO shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Aptose Biosciences in a report on Wednesday. Zacks Investment Research downgraded shares of Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Monday, April 16th. ValuEngine upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating in a report on Monday, June 18th. Finally, Roth Capital set a $6.00 target price on shares of Aptose Biosciences and gave the company a “buy” rating in a report on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $6.38.

Aptose Biosciences traded down $0.03, hitting $3.02, during trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 168,649 shares, compared to its average volume of 267,487. Aptose Biosciences has a 1-year low of $1.30 and a 1-year high of $4.55. The company has a market capitalization of $101.91 million, a PE ratio of -5.81 and a beta of 2.40.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.10). research analysts predict that Aptose Biosciences will post -0.89 earnings per share for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading: Investing in Growth Stocks

Insider Buying and Selling by Quarter for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply